| Overall | Secukinumab | TNFis |
---|---|---|---|
n (%) | n (%) | n (%) | |
6Â months | |||
 ACR20 response | n = 194 | n = 75 | n = 105 |
80 (41.2%) | 34 (45.3%) | 41 (39.0%) | |
 ACR50 response | n = 194 | n = 75 | n = 105 |
57 (29.4%) | 25 (33.3%) | 28 (26.7%) | |
 ACR70 response | n = 199 | n = 77 | n = 108 |
34 (17.1%) | 14 (18.2%) | 18 (16.7%) | |
12Â months | |||
 ACR20 response | n = 189 | n = 74 | n = 100 |
66 (34.9%) | 26 (35.1%) | 36 (36.0%) | |
 ACR50 response | n = 191 | n = 75 | n = 101 |
51 (26.7%) | 22 (29.3%) | 26 (25.7%) | |
 ACR70 response | n = 196 | n = 76 | n = 105 |
36 (18.4%) | 13 (17.1%) | 21 (20.0%) |